Probenecid Inhibition of Organic Anion Secretion

Why OAT Inhibition Changes Both Plasma and Urine

Probenecid can inhibit organic anion transporters (OATs) that contribute to uptake of organic anion substrates from blood into proximal tubular cells. Reducing that uptake can lower active renal secretion. The result is not simply “less drug in urine”: secretion is one route of systemic elimination, so its inhibition can also increase plasma exposure and change how much of a dose has reached urine by a given time.

The useful prediction requires linking three quantities: probenecid exposure at the transporter, the remaining secretory clearance, and the substrate’s total elimination. A renal PBPK model can represent more anatomical detail, but a reduced clearance model makes this connection transparent. It is appropriate when the substrate is in a linear range and the other renal and systemic processes can be treated as unchanged during inhibition.

A Reduced Model for Probenecid Inhibition

Assume that substrate elimination is linear over the concentration range considered; filtration is proportional to unbound plasma concentration; and active secretion is not saturated by the substrate. Let \(CL_{\mathrm{sec},0}\) denote the secretory clearance without probenecid. For competitive inhibition at the transporter, the low-substrate approximation gives

Here \(I_{\mathrm{u}}\) is the unbound probenecid concentration at the relevant transporter site, and \(K_i\) is the inhibition constant expressed in the same concentration units. The equation assumes that the site concentration is known or can be represented by the value used in the calculation. It also assumes that inhibition is reversible and competitive, and that probenecid does not alter substrate binding, GFR, transporter abundance, or other clearance pathways.

The low-substrate condition matters. For a competitive inhibitor and finite substrate concentration \(S\), the transporter rate is proportional to \(S/[K_m(1+I_{\mathrm{u}}/K_i)+S]\). The ratio of inhibited to uninhibited rate is then \((K_m+S)/[K_m(1+I_{\mathrm{u}}/K_i)+S]\), not generally \(1/(1+I_{\mathrm{u}}/K_i)\). The simpler clearance multiplier above follows when \(S\) is small relative to \(K_m\).

For a one-compartment systemic model with plasma concentration \(C\), apparent volume \(V\), and dose input rate \(R_{\mathrm{in}}(t)\), total clearance is

\(CL_{\mathrm{nr}}\) is nonrenal clearance. The filtered and secreted amounts enter urine in this reduced model, so the urinary excretion rate is \(CL_{\mathrm{r}}C\). If reabsorption is important, this rate and the renal clearance expression must be modified; filtration and secretion cannot then be equated directly with net urinary appearance.

From Secretion to Plasma Exposure

For a linear model after an intravenous dose \(D\), integrating the concentration-time curve gives \(AUC=D/CL_{\mathrm{tot}}\). This follows from the amount balance: with no drug remaining in the body at the end of the interval, the administered dose equals total clearance multiplied by AUC. Consequently, the AUC ratio with and without inhibitor is the ratio of the corresponding total clearances in the opposite order. The effect depends on how much baseline total clearance was actually supplied by secretion.

Why Urinary Excretion Depends on the Observation Time

The ultimate fraction of dose in urine is not the same as the fraction excreted by a specified time. Following an intravenous bolus in the one-compartment model, \(C(t)=(D/V)e^{-CL_{\mathrm{tot}}t/V}\). Since the urinary excretion rate is \(CL_{\mathrm{r}}C(t)\), integration from zero to \(t\) yields

This result assumes constant clearances, complete collection of the amount entering urine, and no lag or transit delay between renal transport and measured urine. It distinguishes the fraction of dose assigned to the renal route, \(CL_{\mathrm{r}}/CL_{\mathrm{tot}}\), from the fraction of that route’s eventual amount that has appeared by time \(t\), \(1-e^{-CL_{\mathrm{tot}}t/V}\).

Steady Input and the Meaning of Urinary Rate

A higher plasma concentration does not guarantee a higher urinary excretion rate. At a given time the rate is the product of plasma concentration and renal clearance. At steady state during constant systemic input \(R_0\), the model gives \(C_{\mathrm{ss}}=R_0/CL_{\mathrm{tot}}\); the steady urinary rate is then \(CL_{\mathrm{r}}R_0/CL_{\mathrm{tot}}\). This makes the competing effects of increased concentration and reduced renal clearance explicit.

Diagnostics, Alternatives, and Limits

A useful model should be checked against both plasma and urine observations. Plasma exposure constrains total elimination, while timed urinary amounts and excretion rates provide information about renal disposition. If plasma AUC rises as predicted but renal recovery does not fall as expected, possible explanations include incorrect site exposure, active reabsorption, incomplete urine collection, delayed appearance in urine, changes in filtration, or an inaccurate allocation of total clearance to secretion. A plasma concentration alone generally cannot establish which renal pathway changed.

The inhibition equation is a static approximation. A more detailed renal PBPK model can represent unbound probenecid concentration over time at the basolateral transporter, substrate uptake, intracellular accumulation, apical efflux, and tubular transit. If inhibitor concentration changes appreciably during the dosing interval, then \(CL_{\mathrm{sec}}\) is time-varying and the concentration equation must be integrated with that time-varying clearance rather than evaluated at one fixed \(I_{\mathrm{u}}\). If OAT uptake and apical efflux act in series, inhibiting uptake may not reduce net secretion in direct proportion when another step is rate-limiting.

Alternative predictions include using an empirical change in total renal clearance, or fitting a mechanistic transporter model to concentration and urine data. An empirical clearance change can summarize a measured interaction but may not extrapolate reliably to another dose, inhibitor exposure, or substrate. The mechanistic model offers an interpretable link to OAT inhibition but needs transporter and site-exposure information. Neither approach removes the need to account for filtration, reabsorption, parallel secretory routes, and nonrenal elimination where relevant.

• Assuming total clearance falls by the secretory inhibition percentage. Only the secretory component is scaled by the simple inhibition factor; filtration and nonrenal clearance remain in the total.
• Using total probenecid concentration as site concentration without justification. The equation uses unbound inhibitor concentration at the transporter. Plasma total concentration is not automatically an adequate substitute.
• Equating a timed urine amount with the eventual renal fraction. Finite-time recovery also depends on how rapidly substrate is eliminated and on urine transit and collection.
• Applying the low-substrate approximation to saturated transport. When substrate concentration is not small relative to \(K_m\), use the full competitive rate expression or a suitable dynamic transporter model.